

Lupin launches triple-dose FDC for COPD management

The drug will be marketed as a twice-daily, single-strength fixed dose for the long-term management and treatment of COPD patients.



Mumbai: Lupin Limited has launched a fixed-dose triple combination metered-dose inhaler (MDI), Formoflo-G for chronic obstructive pulmonary disease (COPD) in India.

It combines glycopyrronium bromide, formoterol fumarate and fluticasone propionate and will be marketed as a twice-daily, single-strength fixed dose for the long-term management and treatment of patients.

“Formoflo-G brings together three established therapies in a single inhaler. It strengthens Lupin’s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients,” said Rajeev Sibal, President – India Region Formulations, Lupin.

COPD is a progressive lung disease that blocks airflow and affects more than 55 million people in India.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/lupin-launches-triple-dose-fdc-for-copd-management/134733424>